NYSE · CRL
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
$359.41▼ 4.44% ($16.69)at close
After hours$365.29▲ 1.64%7:07 PM ET
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 20.3% revenue growth a year for 10 years. Our scenarios assume 0.6–4.4%.
That's 6.4× its past 4-year pace.
Value per share
Base case
$48.70
Price used $359.41 is 7.4× this
USD · TTM ending Jun 27, 2026 · Price Oct 30, 8:00 PM UTC
Revenue each value needs
Revenue today $4B. The price needs $25.5B by 2036. Base case: $4.3B. At its recent pace: $5.5B. Bear to Bull: $4.2B to $6.1B.
Revenue today $4B. The price needs $25.5B by 2036. Base case: $4.3B. At its recent pace: $5.5B. Bear to Bull: $4.2B to $6.1B.
Revenue in 2036
today $4B
+$21.1Bmore than the Base case · 5.9×
Value per share · Base case
$48.70
Price $359.41
7.4× this
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 12.3%
- Discount rate
- 9.8%
USD · TTM ending Jun 27, 2026 · Price Oct 30, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 100.66% over the last year. Revenue declined 0.74% over the trailing twelve months. Operating margin moved from 3.09% to 12.35%. Free cash flow declined 35.94% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 12.35%. A decisive move in revenue — currently down 0.74% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
27
Buy
10
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 4, 2026
Q3 FY26 · EPS est $2.97 · Revenue est $960.4M
Same quarter, year over year
FY26 YTD -7.0%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $5.08 vs $5.46 · 0 of 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $10.28
- -0.4%
- FY24
- $10.32
- —
Q2 FY26
Reported Aug 5, 2026 · Latest
HoverTap a cell to inspect
Actual
$3.02
Estimate
$2.74
Year over year
-3.2%
Vs prior quarter
+46.6%
Institutional Sentiment
Charles River Laboratories International, Inc. · CRL
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.